PlumX Metrics
Embed PlumX Metrics

Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy

American Journal of Health-System Pharmacy, ISSN: 1535-2900, Vol: 70, Issue: 4, Page: 343-349
2013
  • 10
    Citations
  • 0
    Usage
  • 27
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Purpose. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated. Methods. All data were retrospectively collected from the Kyushu University Hospital's electronic medical record system. Patients age 20 years or older with hematologic malignancies who received multiday chemotherapy were included in the study. All patients received 3 mg of granisetron i.v. 30 minutes before chemotherapy administration. Patients in the aprepitant group received 125 mg of aprepitant orally 60-90 minutes before administration of the first moderately to highly emetogenic chemotherapy (day 1). On day 2 or thereafter, an 80-mg oral dose of aprepitant was administered in the morning for up to five days. The primary endpoint was the percentage of patients who achieved complete response (CR). Results. A total of 42 patients were treated with aprepitant and granisetron as antiemetic prophylaxis between April and December 2010 (aprepitant group), and 40 patients were treated with only granisetron between March 1, 2009, and March 31, 2010, before the introduction of aprepitant. The percentage of patients who achieved CR in the aprepitant group was significantly higher than that in the control group (p = 0.01). Factors that were significantly associated with non-CR included the prophylactic use of aprepitant and chemotherapies containing ≥4 g/m/day of cytarabine. The rates of adverse drug events (ADEs) did not significantly differ between groups. Conclusion. The addition of aprepitant to granisetron increased the antiemetic effect without influencing ADEs in patients treated with moderately to highly emetogenic multiday chemotherapy for hematologic malignancies. Copyright © 2013, American Society of Health-System Pharmacists, Inc.

Bibliographic Details

Uchida, Mayako; Ikesue, Hiroaki; Kato, Koji; Ichinose, Kimiko; Hiraiwa, Hiromi; Sakurai, Asako; Takenaka, Katsuto; Iwasaki, Hiromi; Miyamoto, Toshihiro; Teshima, Takanori; Egashira, Nobuaki; Akashi, Koichi; Oishi, Ryozo

Oxford University Press (OUP)

Health Professions; Pharmacology, Toxicology and Pharmaceutics; Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know